硼替佐米治疗以肾功能不全为首发症状的多发性骨髓瘤的研究  

Bortezomib in the treatment of multiple myeloma patients with renal dysfunction as initial symptom

作　　者：辜学忠[1] 闻艳[1] 姚翔媚 陆智祥[1] 虞利群[1] 史克倩[1] Gu Xuezhong;Wen Yan(Corresponding author);Yao Xiangmei;Lu Zhixiang;Yu Liqun;Shi Keqian(Department of Hematology,the First People's Hospital of Yunnan Province 650032)

机构地区：[1]云南省第一人民医院血液科,650032

出　　处：《中国社区医师》2016年第32期47-47,49,共2页Chinese Community Doctors

基　　金：云南省卫生科技计划项目(编号:2011WS0002)~~

摘　　要：目的:探讨以肾功能不全为首发症状的多发性骨髓瘤采用硼替佐米治疗的临床疗效。方法:以肾功能不全为首发症状的初治多发性骨髓瘤患者20例,平分成两组,对研究组给予BDT方案治疗(硼替佐米+地塞米松+沙利度胺),对照组给予CDT方案治疗(环磷酰胺+地塞米松+沙利度胺),观察两组治疗效果。结果:两组CR、PR、SD、PD和OR差异有统计学意义(P<0.05)。结论:硼替佐米方案治疗以肾功能不全为首发症状的多发性骨髓瘤效果显著,可明显改善肾功能,安全、可靠,可作为靶向性治疗药物。Objective:To investigate the clinical curative effect of bortezomib in the treatment of multiple myeloma patients with renal dysfunction as initial symptom.Methods:20 multiple myeloma patients with renal dysfunction as initial symptom for initial treatment were selected.They were randomly divided into the two groups on average.The study group was treated with BDT scheme(bortezomib and dexamethasone and thalidomide).The control group was treated with CDT regimen(cyclophosphamide and dexamethasone and thalidomide).We observed the therapeutic effect of the two groups.Results: The difference on CR,PR,SD,PD and OR between groups was statistically significant(P<0.05).Conclusions:The effect of bortezomib in the treatment of multiple myeloma patients with renal dysfunction as initial symptom is significant.It can obviously improve renal function,safe and reliable,as a targeted therapy drugs.

关 键 词：肾功能不全 多发性骨髓瘤 硼替佐米 

分 类 号：R733.3[医药卫生—肿瘤]